Here’s the direct answer: on July 16, the FDA approved Lipfendra (enlicitide), the first-ever cholesterol pill in a powerful class of medicines called PCSK9 inhibitors — drugs that until now were only available as injections. In studies it lowered “bad” LDL cholesterol by more than half, matching the shots. If your cholesterol has stayed high despite a statin, this is genuinely good news — with a few honest caveats worth understanding before you ask about it.
What the new cholesterol pill actually does
PCSK9 inhibitors work by helping your liver pull more LDL cholesterol out of your blood. They’re very effective — but they’ve only existed as injectable drugs like Repatha and Praluent, given every two to four weeks and requiring refrigeration. Lipfendra delivers the same mechanism as a single once-daily tablet you can keep at room temperature. In two large trials of adults already on the highest statin dose they could tolerate, it lowered LDL by roughly 56–59% compared with placebo — right in line with the injectable versions.
Who this new cholesterol pill is really for
This isn’t a replacement for statins or for a healthy lifestyle — it’s an added tool. It’s likely to matter most for:
- People whose LDL stays high despite a statin. The trials were done in patients already on their maximum tolerated statin dose.
- People with familial hypercholesterolemia — an inherited condition (about 1 in 250 people) that causes very high LDL from a young age and needs lifelong treatment.
- People who need a PCSK9 inhibitor but don’t want injections. A daily pill is far easier to stick with for many.
- Anyone at high cardiovascular risk working to get their numbers lower than a statin alone can manage.
The honest caveats
A new option is exciting, but a good doctor tells you the whole picture. Lipfendra was approved based on how much it lowers LDL — a strong predictor of heart risk — but it doesn’t yet have the years of data proving it prevents heart attacks and strokes that the injectable versions have accumulated (those benefits are expected, but not yet confirmed for the pill). It’s meant to be used alongside diet, exercise, and usually a statin, not instead of them. And as a brand-new brand-name drug, cost and insurance coverage will take time to settle, so what you’d actually pay isn’t clear yet. None of that is a reason to avoid it — just reasons to make the decision thoughtfully.
The bottom line
High cholesterol affects roughly 73 million American adults, and heart disease is still our leading cause of death — so a new, effective, needle-free way to lower LDL is a real step forward. Whether it’s right for you depends on your numbers, your history, what you’re already taking, and your risk. That’s exactly the kind of question your primary care doctor should walk through with you — and importantly, don’t stop or change any cholesterol medication on your own based on this news.
Come visit us today at DocTalker Family Medicine — your direct primary care practice at 370 Maple Ave W, Suite V, Vienna, VA.
Wondering about your cholesterol numbers?
DocTalker members reach their physician directly by phone, text, or video — usually the same day — and we’ll build a heart-health plan around your numbers and history. Call 703-938-4600 or visit doctalker.com.
- U.S. FDA: FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol (July 2026). fda.gov
- Medical News Today: FDA approves new cholesterol pill Lipfendra — why it matters, per experts (July 17, 2026). medicalnewstoday.com
- New England Journal of Medicine: CORALreef trial results for enlicitide (2026). summary via AJMC